about
A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analysesNuMA overexpression in epithelial ovarian cancer.Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry.Proteomic profiling using mass spectrometry--does normalising by total ion current potentially mask some biological differences?Application of the random forest classification method to peaks detected from mass spectrometric proteomic profiles of cancer patients and controls.Integrated multi-level quality control for proteomic profiling studies using mass spectrometry.Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles--initial evaluation using low molecular weight serum peaks.High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-lInitial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigationsA pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease.Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age.Genetic factors influencing the risk of multiple myeloma bone diseasePredicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionThe prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis.miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth.Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and TreatmentPerformance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification.Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.Statistical issues in quality control of proteomic analyses: good experimental design and planning.Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart Failure.Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model.The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaRetinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.Changes in the urinary proteome post-operatively in renal cancer patients - a reflection of tumour or kidney removal?Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison.Cardiac resynchronization therapy outcomes in patients with chronic heart failure: cardiac resynchronization therapy with pacemaker versus cardiac resynchronization therapy with defibrillator.Rate-Response Programming Tailored to the Force-Frequency Relationship Improves Exercise Tolerance in Chronic Heart Failure.Statistical issues in the design and planning of proteomic profiling experiments.The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): stuUrinary biomarker profiling in transitional cell carcinoma.Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study.Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.Biomarkers and response to bevacizumab--response.The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation
P50
Q28732696-8674F590-88AD-4DD0-911D-6CA23DA53869Q31068680-36695663-7B49-4D88-8F48-954AD47D74C3Q33218408-ADA6CE70-A8F0-4745-9283-E36C859E8763Q33311516-BC84876E-0B01-4987-B775-661E8A102AA3Q33321920-D826D6E3-9867-4E48-BB05-13D74E16F036Q33389590-FF542266-1B92-4939-806E-8A34AC6940A9Q33399808-86872FE9-7B20-40A9-ACEA-927FD9621D3AQ33416028-10825FB0-B11F-494C-ABD7-FD199C3126BEQ33758692-117D4152-40BC-4F60-8ABE-9DA00AC0AE78Q33990550-9ABC2813-6FCE-4E2B-B1CC-0D7A3C83BBDEQ34426108-7D851AE3-593A-4FFD-88AA-AAD8672EE81BQ34674841-8F0DBE61-A0C3-4408-B7AA-C8E43B9D827EQ34916073-5C24B7FF-2DF9-4D6F-A184-94FCA69B84C7Q35094175-D9E9BEBA-2E3D-464F-A0EC-0B50D86BB942Q35423674-0677E033-4A9F-44E9-8C76-2A17B5564389Q36341406-95199484-F798-4785-AC5D-0CC2AB048887Q36511162-A8CE1C04-6E3F-4572-B8C0-A8362E79A790Q36731411-03BCAF8B-8A93-4EE0-A56A-BE4E87E47C88Q36859699-8FCC2311-2317-48EA-BA91-95BF4E402295Q37501815-3CF50AF8-4189-4776-95CD-2F04931F0A45Q37836674-B543AAB6-E62F-45CA-86C1-E0E0179DDF29Q38388280-D438B347-5164-4D8D-8B7E-E80F7B7110D1Q38475205-C6417FCB-7BCB-49C4-B70E-66E37AE9683DQ38742055-6F0602BF-DDA7-4F72-9F78-43B4C6B3337DQ39832349-02300FB5-6FE0-4320-A715-B17844F4FFDFQ39865719-E42871D6-AA08-4FE9-BEC5-9C09AA9DA19DQ40669032-D1BA4A8E-C5AB-48FA-9345-F6D147A5C54AQ41919666-076BDCE1-6BD2-4610-976E-CFD6D201688BQ44347917-210E123A-B8CE-4DCB-8F58-786DF1D8FAAEQ46300489-C5E98CA1-74D0-49D5-9077-A8303F17ABA2Q46609661-B6432583-6E7D-41F1-B635-7FEDE2910DD8Q47768449-505B3F6B-80C6-4989-B7DC-3C6F91DF2384Q49954439-0B2049B5-1E3A-43DC-AD13-BB2DD971DD8CQ51014123-7E871070-DEAB-4818-ABE3-B82AE8B1FE04Q51411892-E585C70A-3FEC-4860-AFBE-C9116A728DEEQ51932949-7268146E-0AC1-433C-9618-477C74D27B59Q52801424-57D8C56C-C1B6-4037-82F1-7A9BC8B21885Q52818331-09C7E60E-0D51-4B5C-BEE2-B38BF2450EF4Q52840229-E777AC01-0BA6-4B63-8708-C4D14E9FFABFQ56428844-5A0C9591-1B71-46C7-A871-B7A36DB501DA
P50
description
hulumtues
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
David A Cairns
@cy
David A Cairns
@en-gb
David A Cairns
@nl
David A Cairns
@sl
David A. Cairns
@en
David A. Cairns
@es
type
label
David A Cairns
@cy
David A Cairns
@en-gb
David A Cairns
@nl
David A Cairns
@sl
David A. Cairns
@en
David A. Cairns
@es
altLabel
David Cairns
@cy
David Cairns
@en
David Cairns
@en-gb
prefLabel
David A Cairns
@cy
David A Cairns
@en-gb
David A Cairns
@nl
David A Cairns
@sl
David A. Cairns
@en
David A. Cairns
@es
P1053
A-6577-2009
P106
P1153
13604737100
P2031
2005-01-01T00:00:00Z
P21
P31
P3829
P496
0000-0002-2338-0179